Drug Overview
Inlyta (axitinib; Pfizer) is a kinase inhibitor designed to selectively inhibit vascular endothelial growth factor receptor-1 (VEGFR-1), VEGFR-2, and VEGFR-3. These receptors are believed to be implicated in angiogenesis, tumor growth, and metastasis.
Analyst Outlook
Inlyta was approved by the US Food and Drug Administration (FDA) in January 2012 for use in the treatment of patients with advanced renal cell cancer (RCC) after failure of one prior systemic therapy (Pfizer press release, 2012a). Inlyta subsequently received EU marketing authorization for the treatment of advanced RCC after failure of prior treatment with Sutent (sunitinib; Pfizer) or a cytokine (Pfizer press release, 2012b). These approvals were based on the results of a head-to-head Phase III trial with Nexavar (sorafenib; Bayer/Amgen), an established therapy in the second-line treatment of advanced RCC.
Inlyta (axitinib; Pfizer) is a kinase inhibitor designed to selectively inhibit vascular endothelial growth factor receptor-1 (VEGFR-1), VEGFR-2, and VEGFR-3. These receptors are believed to be implicated in angiogenesis, tumor growth, and metastasis.
Analyst Outlook
Inlyta was approved by the US Food and Drug Administration (FDA) in January 2012 for use in the treatment of patients with advanced renal cell cancer (RCC) after failure of one prior systemic therapy (Pfizer press release, 2012a). Inlyta subsequently received EU marketing authorization for the treatment of advanced RCC after failure of prior treatment with Sutent (sunitinib; Pfizer) or a cytokine (Pfizer press release, 2012b). These approvals were based on the results of a head-to-head Phase III trial with Nexavar (sorafenib; Bayer/Amgen), an established therapy in the second-line treatment of advanced RCC.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES
